1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)amino]- manufacturers
|
| | 1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)amino]- Basic information |
| Product Name: | 1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)amino]- | | Synonyms: | 1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)amino]-;SelexipagImpurity14;Selexipag Impurity 16;N-(4-((5,6-diphenylpyrazin-2-yl)oxy)butyl)-N-isopropyl-5,6-diphenylpyrazin-2-amine;Selexipag Impurity 09;Selexipag impurity 09(INT3-D) | | CAS: | 2514706-51-3 | | MF: | C20H21N3O | | MW: | 319.4 | | EINECS: | | | Product Categories: | | | Mol File: | 2514706-51-3.mol | ![1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)amino]- Structure](CAS/20210305/GIF/2514706-51-3.gif) |
| | 1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)amino]- Chemical Properties |
| Boiling point | 492.5±45.0 °C(Predicted) | | density | 1.170±0.06 g/cm3(Predicted) | | pka | 15.08±0.10(Predicted) |
| | 1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)amino]- Usage And Synthesis |
| Uses | 4-((5,6-Diphenylpyrazin-2-yl)amino)butan-1-ol is a selexipag impurity (S253150). Selexipag is an orally available, highly selective, long-acting prostacyclin (IP) receptor agonist prodrug. It is a potential drug for the treatment of various vascular disorders such as pulmonary arterial hypertension and arteriosclerosis obliterans. |
| | 1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)amino]- Preparation Products And Raw materials |
|